ACEI or not to ACEI: Review on using ACEI and ARBs on COVID-19 patients: Systemic review

Ribhav Walia

doi:10.1101/2023.03.25.23287550

Abstract

Purpose and motivation of this study Angiotensin-converting enzyme inhibitors (ACEI) and Aldosterone receptor blockers (ARBs) are one most commonly used drugs for the treatment of cardiovascular disease among other comorbidities. As multiple studies have shown that covid virus binds to the ACE2 receptor for entry into the cell. ACEI and ARBs are shown to modulate the ACE2 receptor hence, it is important to see if there are any correlations between the use of medicine and the infectivity of COVID-19. The purpose of this study is to find if the use of ACEI /ARBs can in fact increase or decrease the spread of COVID-19.

Method This is a systemic review study during which all studies which helped us answer the question, of how the use of ACEI and ARBs can affect the transmission of the COVID-19 virus, were analyzed and reviewed to draw a conclusion about clinical safety and requirements of ACEI and ARBs in COVID-19 patients.

Result After a complete review of all the available data very conflicting results were found. Many studies showed an increase in the transmission of COVID-19 while others showed a decreased risk of COVID-19 transmission with ACEI and ARBs use. Both results were statistically significant.

Conclusion With these conflicting results the question we started with comes up again. Should we or should we not use ACEI & ARBs with covid patients? What should be the best clinical response with the use of ACEI & ARBs if it modulates transmission? To answer these, one must look not only at the statistically significant results of studies but also at the disease progression without ACEI & ARBs treatment regimes. Due to the small amount of data, there is currently no clear conclusive evidence to suggest that ACE inhibitors either increase or decrease the risk of COVID-19 transmission or the severity of the disease. Thus, more and larger studies should be developed to find a concrete answer. Until that these medicines should not be discontinued as the morbidities of cardiovascular diseases are high, and the use of ACEI and ARBs is central to the treatment.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced are available online at

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027683/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126103/

https://www.sciencedirect.com/science/article/pii/S0735675720302631

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.510461?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924745/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665323/

https://doi.org/10.1038/s41569-019-0244-8

Abbreviations

RAAS: renin angiotensin aldosterone system
RAS: Renin Angiotensin System
ACE: Angiotensin-converting enzyme
ACEI: Angiotensin-converting enzyme inhibitor
ARBs: Aldosterone receptor blockers
WHO: World Health Organisation
TMPRSS2: Transmembrane protease serine-type 2
SARS-CoV2: Severe Acute Respiratory Syndrome Coronavirus 2.
COVID-19: Coronavirus disease 2019
Ang: Angiotensin

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.